Reply:
Winston Dunn, Jeffrey B. Schwimmer – 9 July 2008
Fast break on the fat brake: Mechanism of peroxisome proliferator‐activated receptor‐δ regulation of lipid accumulation in hepatocytes
Danielle B. Andrews, Jeffrey B. Schwimmer, Joel E. Lavine – 9 July 2008
Benefits of “the benefit model” in liver transplantation
W. Ray Kim, Walter K. Kremers – 9 July 2008
Reply:
Nathan A. Johnson, Toos Sachinwalla, Jacob George – 8 July 2008
Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients
Denise Herzog, Dorothée Bouron‐Dal Soglio, Jean‐Christophe Fournet, Steven Martin, Denis Marleau, Fernando Alvarez – 25 June 2008 – Chronic graft dysfunction, manifesting with elevated liver enzymes and histological features of interface hepatitis (IH), is being increasingly recognized as a long‐term problem after liver transplantation. The aim of this study was to characterize our group of post–orthotopic liver transplantation (OLT) patients with respect to clinical, laboratory, and histological signs of IH.
Platelets in liver transplantation: Friend or foe?
Ilona T. A. Pereboom, Ton Lisman, Robert J. Porte – 25 June 2008 – Apart from the well‐known role of blood platelets in hemostasis, there is emerging evidence that platelets have various nonhemostatic properties that play a critical role in inflammation, angiogenesis, tissue repair and regeneration, and ischemia/reperfusion (I/R) injury. All these processes may be involved in the (patho)physiological alterations occurring in patients undergoing liver transplantation.
Split liver transplantation: Will it ever yield grafts for two adults?
Cristiano Quintini, Federico Aucejo, Charles M. Miller – 25 June 2008
Hepatopulmonary syndrome: Use of extracorporeal life support for life‐threatening hypoxia following liver transplantation
Geoffrey M. Fleming, Timothy T. Cornell, Theodore H. Welling, John C. Magee, Gail M. Annich – 25 June 2008 – Hepatopulmonary syndrome is an uncommon complication of nonacute liver failure, and in rare cases, hypoxia may be the presenting sign of liver dysfunction. The condition, once thought to be a contraindication, is improved in most cases by transplantation. There is a significant risk of postoperative, hypoxia‐related morbidity and mortality in patients with hepatopulmonary syndrome.
Effects of double‐filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation
Yasutsugu Takada, Takashi Ito, Yoshihide Ueda, Hironori Haga, Hiroto Egawa, Koichi Tanaka, Shinji Uemoto – 25 June 2008 – Response rates to interferon and ribavirin treatment for recipients with recurrent hepatitis C virus (HCV) infection are suboptimal, particularly for those with genotype 1b and high viral load. The present study evaluated the effects of combining double‐filtration plasmapheresis (DFPP) with pharmacotherapy using interferon plus ribavirin after living donor liver transplantation.